SunTrust Robinson Keeps Clovis Oncology (CLVS) As “Buy”; Has Target Of $90.0000; Ancient Art LP Has Trimmed By $53.66 Million Its Credit Accep Mich (CACC) Position

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Ancient Art Lp decreased Credit Accep Corp Mich (CACC) stake by 54.2% reported in 2017Q4 SEC filing. Ancient Art Lp sold 166,137 shares as Credit Accep Corp Mich (CACC)’s stock rose 1.15%. The Ancient Art Lp holds 140,410 shares with $45.42 million value, down from 306,547 last quarter. Credit Accep Corp Mich now has $6.14B valuation. The stock decreased 3.23% or $10.56 during the last trading session, reaching $316.26. About 93,917 shares traded. Credit Acceptance Corporation (NASDAQ:CACC) has risen 74.80% since April 7, 2017 and is uptrending. It has outperformed by 63.25% the S&P500.

Investment analysts at SunTrust Robinson have $90.0000 TP on Clovis Oncology (NASDAQ:CLVS). SunTrust Robinson’s TP suggests a potential upside of 62.10% from the company’s current stock price. The rating was revealed to investors in analysts report on Friday, 6 April.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on May, 2. They expect $-1.34 earnings per share, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.27 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.51% negative EPS growth.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.81 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

The stock increased 5.85% or $3.07 during the last trading session, reaching $55.52. About 3.47 million shares traded or 178.12% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 7, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Since October 16, 2017, it had 0 insider purchases, and 7 insider sales for $1.62 million activity. IVERS-READ GILLIAN C sold $253,620 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, October 16. SPICKSCHEN THORLEF sold $276,615 worth of stock.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology has $134 highest and $15 lowest target. $68.78’s average target is 23.88% above currents $55.52 stock price. Clovis Oncology had 63 analyst reports since September 10, 2015 according to SRatingsIntel. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Sell” rating by Chardan Capital Markets on Tuesday, October 25. Mizuho downgraded it to “Neutral” rating and $35 target in Monday, November 16 report. The firm earned “Buy” rating on Friday, September 23 by Suntrust Robinson. The firm has “Buy” rating given on Monday, September 18 by Leerink Swann. J.P. Morgan maintained it with “Buy” rating and $7200 target in Thursday, June 1 report. The firm has “Buy” rating by SunTrust given on Friday, September 23. Barclays Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Tuesday, February 27 with “Overweight” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Overweight” rating given on Thursday, January 26 by PiperJaffray. The firm earned “Overweight” rating on Thursday, November 2 by Morgan Stanley. Suntrust Robinson maintained the stock with “Buy” rating in Wednesday, August 24 report.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It dropped, as 35 investors sold Clovis Oncology, Inc. shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Strs Ohio owns 3,100 shares. Gabelli And Communication Inv Advisers reported 0.31% stake. Jefferies Grp Limited Liability Com holds 2,937 shares or 0% of its portfolio. First Republic Inv Mngmt Inc holds 0% or 3,186 shares in its portfolio. Ardsley Advisory Prtnrs stated it has 0.86% in Clovis Oncology, Inc. (NASDAQ:CLVS). Ontario – Canada-based Royal Financial Bank Of Canada has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). C World Gp Holdings A S has 169,700 shares. Birchview Cap L P has invested 0.2% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). State Of Wisconsin Invest Board has invested 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Parametric Port Assocs Ltd Llc stated it has 31,335 shares or 0% of all its holdings. Glg Prtn Limited Partnership holds 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 1,886 shares. Endurant Capital Management L P stated it has 1.41% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Amer Century Companies has 52,155 shares for 0% of their portfolio. Massachusetts-based Putnam Limited Liability has invested 0.15% in Clovis Oncology, Inc. (NASDAQ:CLVS). Swiss Savings Bank invested in 79,050 shares or 0.01% of the stock.

Investors sentiment increased to 1.04 in 2017 Q4. Its up 0.01, from 1.03 in 2017Q3. It increased, as 18 investors sold CACC shares while 60 reduced holdings. 35 funds opened positions while 46 raised stakes. 12.84 million shares or 2.21% less from 13.13 million shares in 2017Q3 were reported. Parametric Associates Limited Liability Co has invested 0.02% in Credit Acceptance Corporation (NASDAQ:CACC). Caxton Associates Lp reported 1,915 shares stake. Neuberger Berman Limited Liability Co owns 19,056 shares or 0.01% of their US portfolio. Schwab Charles Inv Mgmt Inc has 78,372 shares. Pathstone Family Office Limited Liability Company reported 125 shares. Force Management Ltd holds 0.5% of its portfolio in Credit Acceptance Corporation (NASDAQ:CACC) for 1,486 shares. Northern reported 0.01% stake. Envestnet Asset Mngmt has invested 0% in Credit Acceptance Corporation (NASDAQ:CACC). Regions Fin holds 0% or 21 shares. Investmentaktiengesellschaft Fuer Langfristige Investoren Tgv invested in 110,000 shares. Hound Ptnrs Limited Liability has 569,504 shares. Bnp Paribas Arbitrage Sa owns 15,383 shares. Quantum Capital Management Limited Liability Company Nj holds 4.9% in Credit Acceptance Corporation (NASDAQ:CACC) or 50,812 shares. Gabelli Funds Ltd Liability owns 1,000 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 390 shares.

Analysts await Credit Acceptance Corporation (NASDAQ:CACC) to report earnings on May, 7. They expect $6.11 EPS, up 30.84% or $1.44 from last year’s $4.67 per share. CACC’s profit will be $118.58M for 12.94 P/E if the $6.11 EPS becomes a reality. After $5.16 actual EPS reported by Credit Acceptance Corporation for the previous quarter, Wall Street now forecasts 18.41% EPS growth.

Among 12 analysts covering Credit Acceptance Corp (NASDAQ:CACC), 1 have Buy rating, 6 Sell and 5 Hold. Therefore 8% are positive. Credit Acceptance Corp had 29 analyst reports since July 31, 2015 according to SRatingsIntel. Jefferies maintained Credit Acceptance Corporation (NASDAQ:CACC) rating on Wednesday, January 10. Jefferies has “Hold” rating and $332.0 target. Susquehanna initiated Credit Acceptance Corporation (NASDAQ:CACC) on Monday, January 23 with “Neutral” rating. The firm has “Underperform” rating given on Wednesday, May 11 by Macquarie Research. Credit Suisse maintained Credit Acceptance Corporation (NASDAQ:CACC) rating on Tuesday, August 1. Credit Suisse has “Sell” rating and $20000 target. Jefferies maintained the stock with “Hold” rating in Tuesday, October 31 report. The firm has “Market Perform” rating by JMP Securities given on Wednesday, August 26. As per Wednesday, January 31, the company rating was maintained by BMO Capital Markets. The stock has “Hold” rating by Jefferies on Thursday, September 7. Susquehanna maintained Credit Acceptance Corporation (NASDAQ:CACC) on Tuesday, January 30 with “Hold” rating. The rating was downgraded by Credit Suisse on Wednesday, July 27 to “Underperform”.

Credit Acceptance Corporation (NASDAQ:CACC) Institutional Positions Chart